恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

jamc:肝细胞癌患者经动脉化疗栓塞再治疗评分对经动脉化疗栓塞再治疗的决策作用-ag捕鱼平台

文字: 2019-12-17    浏览次数:355    

background

the objective behind this study was to determine that assessment for retreatment with transarterial chemoembolization (art) score is really applicable in patients with hepatocellular carcinoma. 

背景

本研究旨在确定经动脉化疗栓塞再治疗评估(art) 评分在肝细胞癌(hcc)患者中的应用价值。

 

methods

a cross sectional observational study was conducted on all patients with hepatocellular carcinoma of intermediate stage and undergone ≥2 transarterial chemoembolization. art score was assessed before and after each session of transarterial chemoembolization. multi-logistic regression analysis was performed to compare the final outcome of patients with art score of ≥2.5 into groups with two and more than two trans-arterial chemo-embolization sessions. 

方法

采用横断面观察研究对所有行≥2次经动脉化疗栓塞治疗的中期hcc患者进行评估。art评分在每次经动脉化疗栓塞前后进行评估。分为两次和及两次以上的经动脉化学栓塞治疗组,采用多因素logistic回归分析比较art评分≥2.5的患者的最终结局。

 

results

a total of 100 hcc patients were recruited for final analysis. our study participants consisted of total 100 hcc patients. mean child pugh score was 6.1±0.95. in our study, most of the study participants (n=63) had art score of less than 1.5 as compared to art score >2.5 (n=37). a significant proportion of patients with art score of <1.5 prior to second trans-arterial chemo-embolization had better median survival as compared to patients with art score of >2.5, p-value<0.001. patients with art score of more than 2.5 did not show any survival benefit after having 3rd or 4th trans-arterial chemo-embolization session, p=0.47. 

结果

共招募了100hcc患者进行最终分析。其中本研究的参与者共有100hcc患者。child-pugh得分为6.1±0.95。在本研究中,大多数参与者(n=63)art评分低于1.5,其余art评分>2.5 (n=37)。在第二次经动脉化疗栓塞前art评分<1.5的患者中,有相当比例的患者的中位生存期优于art评分>2.5的患者(p<0.001)art评分大于2.5的患者在行第3次或第4次经动脉化疗栓塞治疗后,无任何生存获益(p=0.47)

 

conclusions

our study findings suggest that those hcc patients who receive multiple sessions of tace with a low art score have more favourable outcomes with increased survival rate.

结论

本项研究表明,接受多次taceart评分较低的hcc患者的预后更好,生存率更高。